2022
Linzagolix With and Without Hormonal Add-Back Therapy for the Treatment of Symptomatic Uterine Fibroids: Two Randomized, Placebo-Controlled, Phase 3 Trials
Donnez J, Taylor H, Stewart E, Bradley L, Marsh E, Archer D, Al-Hendy A, Petraglia F, Watts N, Gotteland J, Bestel E, Terrill P, Loumaye E, Humberstone A, Garner E. Linzagolix With and Without Hormonal Add-Back Therapy for the Treatment of Symptomatic Uterine Fibroids: Two Randomized, Placebo-Controlled, Phase 3 Trials. Obstetrical & Gynecological Survey 2022, 77: 741-742. DOI: 10.1097/ogx.0000000000001113.Peer-Reviewed Original Research
2011
Novel Therapies Targeting Endometriosis
Taylor HS, Osteen KG, Bruner-Tran KL, Lockwood CJ, Krikun G, Sokalska A, Duleba AJ. Novel Therapies Targeting Endometriosis. Reproductive Sciences 2011, 18: 814-823. PMID: 21693775, PMCID: PMC4046304, DOI: 10.1177/1933719111410713.Peer-Reviewed Original ResearchConceptsNonhuman primate trialsAnti-inflammatory drugsProgesterone modulatorsEndometrial glandsPainful disordersNovel therapiesCommon causeSelective estrogenAntiangiogenic agentsWomen's qualityPotential therapyRodent modelsEndometriosisTherapyDiseaseStem cellsFurther testingPromising new developmentStatinsEstrogenInfertilityUterusStromaTrials